Cargando…
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
BACKGROUND: In breast cancer (BC), overexpression of HER2 on the primary tumor (PT) is determined by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to stratify samples as negative, equivocal and positive to identify patients (pts) for anti-HER2 therapy. CAP/ASCO guidelines r...
Autores principales: | Grüntkemeier, Lisa, Khurana, Aditi, Bischoff, Farideh Zamaniyan, Hoffmann, Oliver, Kimmig, Rainer, Moore, Mathew, Cotter, Philip, Kasimir-Bauer, Sabine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021056/ https://www.ncbi.nlm.nih.gov/pubmed/35025065 http://dx.doi.org/10.1007/s12282-022-01330-8 |
Ejemplares similares
-
Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
por: Stenehjem, David D, et al.
Publicado: (2014) -
Evaluating Low HER2 Status in Invasive Breast Carcinoma via HER2 Immunohistochemistry, with HER2 FISH Correlation: A Cohort of 112 Patients
por: Ardor, Gokce Deniz, et al.
Publicado: (2023) -
Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
por: Suydam, Camille, et al.
Publicado: (2023) -
The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021) -
HER kinase inhibition in patients with HER2- and HER3-mutant
cancers
por: Hyman, David M., et al.
Publicado: (2018)